USFDA approves next-gen TKI Augtyro for treatment of solid tumors

Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors

Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network

Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network

Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis

Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan

As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore

USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes

Zydus receives USFDA’s tentative approval for Azilsartan Medoxomil and Chlorthalidone Tablets

Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).

Farxiga approved in the US for the treatment of paediatric type-2 diabetes

Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date

USFDA inspection of Lupin’s Nagpur injectable facility with zero 483 observations

Pfizer updates on Phase 3 study of investigational gene therapy for ambulatory boys with Duchenne Muscular Dystrophy

The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment

Kardium announces US$ 104 million in new financing for innovative Atrial Fibrillation Treatment

Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners